BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38245472)

  • 21. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
    Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
    Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
    J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
    J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
    Suzuki SY; Ito K; Ito M; Kawai K
    J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.
    Vonderheid EC; Kantor GR; Telang GH; Bujanouskas P; Kadin ME
    J Cutan Pathol; 2019 Dec; 46(12):913-924. PubMed ID: 31403211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
    Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
    Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
    Ai WZ; Keegan TH; Press DJ; Yang J; Pincus LB; Kim YH; Chang ET
    JAMA Dermatol; 2014 Jul; 150(7):709-15. PubMed ID: 24718769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma.
    Sakamoto M; Miyagaki T; Kamijo H; Oka T; Boki H; Takahashi-Shishido N; Suga H; Sugaya M; Sato S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study.
    Pruksaeakanan C; Teyateeti P; Patthamalai P; Thumrongtharadol J; Chairatchaneeboon M
    Biomed Res Int; 2021; 2021():4057661. PubMed ID: 34235215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
    Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
    J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
    Miyashiro D; Sanches JA
    Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database.
    Su C; Nguyen KA; Bai HX; Cao Y; Tao Y; Xiao R; Karakousis G; Zhang PJ; Zhang G
    J Am Acad Dermatol; 2017 Sep; 77(3):497-502.e2. PubMed ID: 28645647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
    Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States.
    Imam MH; Shenoy PJ; Flowers CR; Phillips A; Lechowicz MJ
    Leuk Lymphoma; 2013 Apr; 54(4):752-9. PubMed ID: 23004352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age, race, sex, stage, and incidence of cutaneous lymphoma.
    Wilson LD; Hinds GA; Yu JB
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):291-6. PubMed ID: 23040434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis.
    Giberson M; Mourad A; Gniadecki R
    Dermatology; 2017; 233(4):320-325. PubMed ID: 29169156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
    Horna P; Moscinski LC; Sokol L; Shao H
    Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.